Functional investigation of fas ligand expressions in human non-small cell lung cancer cells and its clinical implications

Annals of Thoracic Surgery

Volumn 95, Issue 2, 2013, Pages 412-418

  Lin, Yidan ^a   Liu, Lunxu ^a   Zhang, Ting ^a   Liu, Jin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; LEUKEMIA CELL LINE; LUNG NON SMALL CELL CANCER; PRIMARY LUNG CANCER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; WESTERN BLOTTING;

CARCINOMA, NON-SMALL-CELL LUNG; FAS LIGAND PROTEIN; HUMANS; IMMUNITY, CELLULAR; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84872810452     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2012.08.012     Document Type: Article

References (31)

1. T. Brunner, C. Wasem, R. Torgler, I. Cima, S. Jakob, N. Corazza Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology Semin Immunol 15 2003 167 176
2. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green, T.A. Ferguson Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1995 1189 1192
3. Y. Jee, E.M. Noh, E.S. Cho, H.Y. Son Involvement of the Fas and Fas ligand in testicular germ cell apoptosis by zearalenone in rat J Vet Sci 11 2010 115 119
4. T. Reimer, C. Herrnring, D. Koczan FasL:Fas ratio-a prognostic factor in breast carcinomas Cancer Res 60 2000 822 828
5. M. Mottolese, S. Buglioni, C. Bracalenti Prognostic relevance of altered Fas (CD95)-system in human breast cancer Int J Cancer 89 2000 127 132
6. S. Munakata, T. Enomoto, M. Tsujimoto Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms Br J Cancer 82 2000 1446 1452
7. S. Munakata, O. Watanabe, K. Ohashi, H. Morino Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance Am J Clin Pathol 123 2005 879 885
8. Y. Ito, M. Monden, T. Takeda The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma Br J Cancer 82 2000 1211 1217
9. A. Zimmermann, A. Kappeler, H. Friess, M.W. Büchler Hepatocellular carcinoma with an unusual medullary-like histology and signs of regression ("medullary-like hepatocellular carcinoma") Dig Liver Dis 34 2002 748 753
10. E. Song, J. Chen, N. Ouyang, F. Su, M. Wang, U. Heemann Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer Br J Cancer 85 2001 1047 1054
11. K. Neuber, B. Eidam Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival Onkologie 29 2006 361 365
12. A.E. Steiert, D. Sendler, W.F. Burke, C.Y. Choi, K. Reimers, P.M. Vogt Attack the tumor counterattack-c-Flip expression in Jurkat-T-cells protects against apoptosis induced by coculture with SW620 colorectal adenocarcinoma cells J Surg Res 176 2011 133 140
13. V.M. Abrahams, S.L. Straszewski, M. Kamsteeg Epithelial ovarian cancer cells secrete functional Fas ligand Cancer Res 63 2003 5573 5581
14. T. Waku, T. Fujiwara, J. Shao Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer J Immunol 165 2000 5884 5890
15. K. Seino, N. Kayagaki, K. Okumura, H. Yagita Antitumor effect of locally produced CD95 ligand Nat Med 3 1997 165 170
16. I. Tinhofer, H. Wykypiel, I. Marschitz, T. Henn, R. Greil Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway Gut 46 2000 738 740
17. H.K. Oie, E.K. Russell, D.N. Carney, A.F. Gazdar Cell culture methods for the establishment of the NCI series of lung cancer cell lines J Cell Biochem Suppl 24 1996 24 31
18. B. Van den Eynde, P. Hainaut, M. Herin Presence on a human melanoma of multiple antigens recognized by autologous CTL Int J Cancer 44 1989 634 640
19. J.P. Aubry, A. Blaecke, S. Lecoanet-Henchoz Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity Cytometry 37 1999 197 204
20. T.A. Ferguson, D.R. Green Fas-ligand and immune privilege: the eyes have it Cell Death Differ 8 2001 771 772
21. P.H. Krammer CD95's deadly mission in the immune system Nature 407 2000 789 795
22. A. Khar, C. Varalakshmi, B.V. Pardhasaradhi, A. Mubarak Ali, A.L. Kumari Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion Cell Immunol 189 1998 85 91
23. A.E. Ryan, F. Shanahan, J. O'Connell, A.M. Houston Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo Cancer Res 65 2005 9817 9823
24. J.W. Kim, E. Wieckowski, D.D. Taylor, T.E. Reichert, S. Watkins, T.L. Whiteside Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes Clin Cancer Res 11 2005 1010 1020
25. T.E. Reichert, L. Strauss, E.M. Wagner, W. Gooding, T.L. Whiteside Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma Clin Cancer Res 8 2002 3137 3145
26. M.W. Cruise, J.R. Lukens, A.P. Nguyen, M.G. Lassen, S.N. Waggoner, Y.S. Hahn Fas ligand is responsible for CXCR3 chemokine induction in CD4+ T cell-dependent liver damage J Immunol 176 2006 6235 6244
27. H. Yokomizo, K. Yoshimatsu, K. Ishibashi Fas ligand expression is a risk factor for liver metastasis in colorectal cancer with venous invasion Anticancer Res 23 2003 5221 5224
28. W.-W. Sung, Y.-C. Wang, Y.-W. Cheng A polymorphic-844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer Clin Cancer Research 17 2011 5991 5999
29. I. Viard-Leveugle, S. Veyrenc, L.E. French, C. Brambilla, E. Brambilla Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma J Pathol 201 2003 268 277
30. X. Zhang, X. Miao, T. Sun Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer J Med Genet 42 2005 479 484
31. I. Sipo, A. Hurtado Picó, X. Wang An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy J Mol Med (Berl) 84 2006 215 225